Evidence map›Paper›PMID 41542660›Full record

ArticlemedRxiv : the preprint server for health sciences2026

Molecular decoupling of lineage identity and morphology in aggressive variant prostate cancer.

Chennan Li, JuanJuan Yin, Melissa L Abel, Dana S Vargas Solivan, Kinjal Bhadresha, Sumeyra Kartal, Samantha Nichols, Kanak Parmar, Joseph Twohig, Tri M Truong and 5 more

Abstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in medRxiv : the preprint server for health sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

15 authors.

Chennan LiGenitourinary Malignancies Branch, National Cancer Institute, Bethesda, MD, USA.ORCID 0000-0002-4520-4694
JuanJuan YinGenitourinary Malignancies Branch, National Cancer Institute, Bethesda, MD, USA.ORCID 0000-0001-6739-5463
Melissa L AbelGenitourinary Malignancies Branch, National Cancer Institute, Bethesda, MD, USA.ORCID 0000-0001-8941-0206
Dana S Vargas SolivanGenitourinary Malignancies Branch, National Cancer Institute, Bethesda, MD, USA.ORCID 0009-0007-6275-2506
Kinjal BhadreshaGenitourinary Malignancies Branch, National Cancer Institute, Bethesda, MD, USA.ORCID 0009-0007-0718-5078
Sumeyra KartalGenitourinary Malignancies Branch, National Cancer Institute, Bethesda, MD, USA.ORCID 0000-0002-6728-7080
Samantha NicholsDevelopmental Therapeutics Branch, National Cancer Institute, Bethesda, MD, USA.ORCID 0000-0003-4003-6780
Kanak ParmarDevelopmental Therapeutics Branch, National Cancer Institute, Bethesda, MD, USA.ORCID 0000-0001-7757-887X
Joseph TwohigGenitourinary Malignancies Branch, National Cancer Institute, Bethesda, MD, USA.ORCID 0009-0009-5147-9959
Tri M TruongGenitourinary Malignancies Branch, National Cancer Institute, Bethesda, MD, USA.
Cindy H ChauGenitourinary Malignancies Branch, National Cancer Institute, Bethesda, MD, USA.ORCID 0000-0002-6928-3833
Kathleen KellyLaboratory of Genitourinary Cancer Pathogenesis, National Cancer Institute, Bethesda, MD, USA.
William D FiggGenitourinary Malignancies Branch, National Cancer Institute, Bethesda, MD, USA.ORCID 0000-0003-2428-5613
Anish ThomasDevelopmental Therapeutics Branch, National Cancer Institute, Bethesda, MD, USA.ORCID 0000-0003-3293-3115
Adam G SowalskyGenitourinary Malignancies Branch, National Cancer Institute, Bethesda, MD, USA.ORCID 0000-0003-2760-1853

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Aggressive variant prostate cancer (AVPC) is a lethal subtype of prostate cancer characterized by its androgen independence, resistance to chemotherapy, and display of neuroendocrine features which can emerge either de novo or via transformation after a prior diagnosis of adenocarcinoma. The poor clinical outcomes in patients with AVPC are associated with its profound molecular heterogeneity. In this study, we analyzed 23 consecutive AVPC cases treated at a dedicated small-cell clinic (2017-2025) using clinicogenomic and transcriptomic profiling. Transformed AVPC exhibited significantly shorter overall survival times than de novo AVPC (11.8 vs 26.0 months, P < 0.001). Integrative genomic analyses identified residual androgen signaling in subsets of cases harboring neuroendocrine lineage programs, highlighting a decoupling of lineage identity and morphology. To facilitate mechanistic and pharmacologic studies, we established NCI-LYM-1, a patient-derived organoid/PDX from an AR-negative, ASCL1+/SYP+ lymph node metastasis, which faithfully recapitulates the donor tumor's molecular and phenotypic features. Short- and long-read whole-genome sequencing combined with optical genome mapping identified biallelic inactivation of

Identifiers

PMID41542660
PMCPMC12803401

What OpenQuestion holds

Textmetadata
LicenceCC0
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.